A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
NCT01476657 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2021-03-17
Summary
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
Conditions
Interventions
- DRUG
-
IPI-145 (duvelisib)
Oral Twice A Day (BID) Dosing
Sponsors & Collaborators
-
SecuraBio
lead INDUSTRY
Principal Investigators
-
Hagop Youssoufian, MD · Verastem, Inc.
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2016-12-31
- Completion
- 2017-01-31
Countries
- United States
Study Locations
More Related Trials
-
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
NCT00005967 ·Status: COMPLETED ·Phase: PHASE1
-
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
NCT02871323 ·Status: WITHDRAWN ·Phase: PHASE1
-
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT05086315 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
NCT01841723 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
NCT02158091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
NCT03755154 ·Status: TERMINATED ·Phase: PHASE1
-
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
NCT02403271 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01757639 ·Status: COMPLETED ·Phase: PHASE1
-
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01500733 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
NCT04842370 ·Status: UNKNOWN ·Phase: PHASE1
-
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02028039 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
NCT01435720 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
NCT02684617 ·Status: TERMINATED ·Phase: PHASE1
-
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
NCT04512716 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
NCT02109627 ·Status: TERMINATED ·Phase: PHASE1
-
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
NCT02979366 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
NCT03514017 ·Status: TERMINATED ·Phase: PHASE2
-
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
NCT04018248 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
NCT02885766 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
NCT00003997 ·Status: COMPLETED ·Phase: PHASE1
-
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
NCT04353479 ·Status: UNKNOWN ·Phase: PHASE2
-
Dose Escalation of IPI-493 in Hematologic Malignancies
NCT01193491 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
NCT03588598 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
NCT02011945 ·Status: COMPLETED ·Phase: PHASE1
-
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00101296 ·Status: COMPLETED ·Phase: PHASE1